ABSTRACT BACKGROUND Balloon catheters have been designed to facilitate pulmonary vein (PV) isolation in patients with
T he mainstay of catheter-based therapy for patients with paroxysmal atrial fibrillation (AF) is pulmonary vein (PV) isolation (1) .
Despite high rates of acute electrical isolation, longterm efficacy is mainly limited by PV reconnections (2, 3) . This may be attributable to the technical difficulty in achieving a transmural and contiguous ring of necrosis around the PVs with point-by-point ablation. To facilitate this process, balloon catheters using a variety of energy sources, including radiofrequency, laser, and cryoenergy, have been introduced (4) (5) (6) . Although many of these balloon catheters share similar features, the visually guided laser balloon (VGLB) is unique in that it uses: 1) a compliant, variable diameter balloon, thus allowing a single balloon catheter to accommodate multiple PV sizes/shapes; 2) a 2- 
METHODS
The study protocol was approved by the institutional review boards at each of the 21 sites in the United
States. Of these sites, 19 entered the study's randomized phase (Online Appendix). Two sites enrolled subjects into the training phase of the study but did not randomize any patients. The study design stipulated that only randomized patients would be included in the primary analyses. All patients enrolled in the study provided written informed consent.
Patients with drug-refractory paroxysmal AF were enrolled in the study. Inclusion criteria included: $2 symptomatic AF episodes ($1 min) within the previous 6 months; 1 Dukkipati et al. Using the deflectable sheath, the VGLB catheter was inflated at the ostium of the target PV. Under visual guidance, ablation lesions were delivered in a circumferential, contiguous, and overlapping manner around the PV. After placement of the initial anatomically guided encircling lesion set, the circular mapping catheter was used to assess electrical PV isolation.
S E P T E M B E R
If the PV was not isolated, the VGLB catheter was again used to deliver lesions to the area of anatomic breakthrough. All PVs were targeted in a similar manner. Additional comparisons between the study groups included the following pre-specified secondary endpoints: 1) percentage of patients with all PVs acutely
Visually Guided PV Isolation Survival analysis utilized the Kaplan-Meier method.
All tests of significance were 2-sided, with p # 0.05
Participants Enrolled (N=366) Patients with paroxysmal atrial fibrillation (PAF) were randomized to ablation using either the VGLB or a standard irrigated radiofrequency ablation catheter (control). Primary efficacy was assessed over 12 months of follow-up. AAD ¼ antiarrhythmic drug; RF ¼ radiofrequency;
VGLB ¼ visually guided laser balloon.
Dukkipati et al.
Visually Guided PV Isolation considered statistically significant. The analyses were conducted using SAS version 9.3 (SAS Institute, Cary, North Carolina).
The primary safety endpoint was pre-specified as a comparison of the rate of patients with 1 or more PAEs between the 2 groups. The null hypothesis was the PAE rate for the VGLB was inferior to the PAE rate for the control device, assuming a noninferiority delta of 8.0%. The primary efficacy endpoint was pre-specified as a comparison of the treatment success rates between the groups. For the primary efficacy endpoint, the null hypothesis was pre-specified that the rate of treatment success for the VGLB was inferior to the success rate of the control device, assuming a noninferiority delta of 15.0%.
RESULTS
In this study, a total of 342 patients (170 VGLB, 172 controls) underwent ablation, and 334 patients (167 each group) were evaluable for the primary efficacy endpoint after 12 months of follow-up ( Figure 1 ). 
The PAE rate was 11.8% in the VGLB group versus 14.5% in controls (absolute difference: À2.8%; upper limit of 95% CI: 3.5%; p ¼ 0.002 for noninferiority) ( Table 3 
DISCUSSION
This is the first multicenter, randomized, controlled study comparing VGLB ablation versus RFA (control). The major finding is that VGLB ablation . The drug-free single-procedure rate of freedom from symptomatic AF or atypical AFL/AT at 12 months was 57.7% in that study versus 63.5% with VGLB in this study. Furthermore, only 83% were able to achieve isolation with the cryoballoon alone; additional "spot" ablation was required in the remaining patients. In the present study, 94.1% of patients were able to achieve electrical isolation of all PVs with the Per the Kaplan-Meier curves, the primary efficacy endpoint was similar for the VGLB (red) and control (blue) groups. The abrupt change in both curves at 90 days reflects treatment failure following the end of the blanking period. VGLB ¼ visually guided laser balloon. The pie charts show treatment success and reasons for failure for the VGLB and control groups. LA ¼ left atrial; PV ¼ pulmonary vein; other abbreviations as in Figure 1 . SAFETY OF VGLB ABLATION. The PAE rates were lower with the VGLB compared with controls, which fulfilled the pre-specified criteria to for noninferiority (11.8% vs. 14.5%; p ¼ 0.002 for noninferiority). These event rates were primarily driven by an 8.2% and a 9.3% rate of cardioversions in the VGLB and control arms, respectively. Stroke rates were 1.2% for the VGLB group and 0.6% in controls (p ¼ 0.56).
Phrenic nerve palsy occurred in 3.5% and 0.6% of patients for the VGLB and control groups, respectively.
These rates are consistent with other experiences with the VGLB (6,10). Although most studies reported complete resolution of the phrenic nerve palsy during follow-up, in this study, the rate of persistent diaphragmatic paralysis at 1 year was 1.8%. However, these rates are less than reported in STOP AF for cryoballoon ablation: 13.5% and 2.5% for reversible and persistent phrenic nerve paralysis (4).
Significant PV stenosis with the VGLB did not occur in this study and, indeed, has never been reported with the VGLB. By contrast, the rate of significant PV stenosis with RFA in this study was 2.9% and was reported to be 3.1% for the cryoballoon in STOP AF. Of note, the rates of these complications are consistent with those reported for RFA (15, 16) .
OPERATOR LEARNING CURVE. As expected with the adoption of any new technology, learning curve effects Values are n (%). *The total PAE rate reflects the number of patients experiencing a PAE rather than the total of the number of PAEs.
PAE ¼ primary adverse event(s); other abbreviations as in Tables 1 and 2 . Visually Guided PV Isolation S E P T E M B E R 2 2 , 2 0 1 5 : 1 3 5 0 -6 0
